Female Sexual Dysfunction - Pipeline Review, H2 2016

Date: December 21, 2016
Pages: 83
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until March 3, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FB289B00808EN
Leaflet:

Download PDF Leaflet

Female Sexual Dysfunction - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction – Pipeline Review, H2 2016, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 6, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction Overview
Therapeutics Development
Pipeline Products for Female Sexual Dysfunction - Overview
Pipeline Products for Female Sexual Dysfunction - Comparative Analysis
Female Sexual Dysfunction - Therapeutics under Development by Companies
Female Sexual Dysfunction - Therapeutics under Investigation by Universities/Institutes
Female Sexual Dysfunction - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Female Sexual Dysfunction - Products under Development by Companies
Female Sexual Dysfunction - Products under Investigation by Universities/Institutes
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Allergan Plc
Apricus Biosciences Inc
Emotional Brain BV
Fabre-Kramer Pharmaceuticals Inc
GlaxoSmithKline Plc
M et P Pharma AG
Palatin Technologies Inc
Re-Pharm Ltd
TherapeuticsMD Inc
Valeant Pharmaceuticals International Inc
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(sildenafil citrate + testosterone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AB-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alprostadil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estradiol acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKW-00GA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gepirone hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S1B-3006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S1B-307 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SIP-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Dopamine D2 Receptor for Sexual Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPT-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TBS-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WC-3011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Female Sexual Dysfunction - Dormant Projects
Female Sexual Dysfunction - Discontinued Products
Female Sexual Dysfunction - Product Development Milestones
Featured News & Press Releases
Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder
Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine
Sep 22, 2016: TherapeuticsMD Announces Multiple Presentations Related to Yuvvexy (TX-004HR) at Two Upcoming Medical Conferences
Sep 19, 2016: TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy (TX-004HR)
Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder
Jul 07, 2016: TherapeuticsMD Announces New Drug Application Submission for Yuvvexy (TX-004HR)
Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies’ New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors
Jun 29, 2016: TherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application
May 14, 2016: TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial
Mar 02, 2016: TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor & Medical Conferences
Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting
Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women’s Sexual Health Annual Meeting
Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction
Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 83

LIST OF TABLES

Number of Products under Development for Female Sexual Dysfunction, H2 2016
Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Female Sexual Dysfunction - Pipeline by Allergan Plc, H2 2016
Female Sexual Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2016
Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H2 2016
Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2016
Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H2 2016
Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H2 2016
Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H2 2016
Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H2 2016
Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H2 2016
Female Sexual Dysfunction - Pipeline by Valeant Pharmaceuticals International Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Female Sexual Dysfunction - Dormant Projects, H2 2016
Female Sexual Dysfunction - Dormant Projects (Contd..1), H2 2016
Female Sexual Dysfunction - Discontinued Products, H2 2016 72

LIST OF FIGURES

Number of Products under Development for Female Sexual Dysfunction, H2 2016
Number of Products under Development for Female Sexual Dysfunction - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Female Sexual Dysfunction - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: